Month: January 2025

Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PT NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 13, 2025, at 4:30 PM PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. A replay of the webcast will be available on TG’s website following the event. ABOUT TG THERAPEUTICSTG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel...

EDISON, N.J., Jan. 09, 2025 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”), America’s leading innovator in the design, sourcing, and manufacturing of zinc-based long duration energy storage (LDES) systems, manufactured in the United States, today announced its participation in upcoming investor events. 27th Annual Needham Growth ConferenceChief Executive Officer Joe Mastrangelo and Chief Financial Officer Nathan Kroeker will virtually attend and present at the 27th Annual Needham Growth Conference on Thursday, January 16, 2025. The event will also include 1×1 investor meetings. Senior Vice President Global Sales and Commercial Operations, Justin Vagnozzi, will speak on a virtual panel ‘Long Duration Energy Storage’ with other industry leaders on Thursday, January 16, 2025, at 12:45...

World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna’s lead indication in ovarian cancer CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) — Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the appointment of Elena Ratner, M.D., M.B.A, to the Board of Directors. Dr. Ratner will spearhead the strategic direction of Eterna’s efforts to combat ovarian cancer, leveraging her extensive expertise in obstetrics, gynecology, and reproductive sciences. Under her leadership, the company aims to accelerate advancements in innovative therapies targeting these high-priority areas in women’s health. This direction is bolstered by Eterna’s recent collaboration with MD Anderson Cancer Center. Announced last month,...

The French Military is expressing interest in Novacium’s silicon-based battery technology MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company specializing in green engineering of silica and silicon-based materials, is pleased to inform its shareholders that its French-based subsidiary, NOVACIUM SAS (“Novacium”), has entered into a strategic collaboration with the French Army to develop high-capacity batteries utilizing Novacium’s silicon-based materials. Novacium’s strategic collaboration with the French Army’s Technical Section (STAT) is part of its initiative to develop prototypes of ultra-high-capacity batteries for a wide range of military applications. These include surveillance systems, electronic sights, anti-drone...

PETAH TIKVA, Israel, Jan. 09, 2025 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, today announced management’s participation in the 27th Annual Needham Growth Conference on Tuesday, January 14, 2025. Mr. Adi Sfadia, the Company’s CEO, and Mr. Gil Benyamini, the Company’s CFO, will be available for one-on-one meetings with investors at the conference. Management will also host a fireside chat on Tuesday, January 14, 2025, at 9:30 am Eastern Time. A live webcast of the fireside chat will be available at www.gilat.com or by accessing a webcast link at https://wsw.com/webcast/needham143/gilt/2252448. To schedule a meeting with management, please contact a Needham representative or email a request to the Gilat investor relations...

VANCOUVER, British Columbia, Jan. 09, 2025 (GLOBE NEWSWIRE) —  Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) reports full year 2024 production of 4,471,824 silver ounces (“oz”) and 39,047 gold oz, for silver equivalent(1) (“AgEq”) production of 7.6 million oz. Fourth quarter production was 824,529 silver oz and 9,075 gold oz for 1.6 million AgEq oz. “After operating at reduced capacity due to the Guanaceví trunnion failure in August, and subsequently resuming full capacity in December, we are satisfied with our production performance in Q4 and producing at the top range of our updated production guidance,” said Dan Dickson, Chief Executive Officer. “The team demonstrated exceptional diligence and commitment throughout the 15 week recovery period, ensuring the timely fabrication and...

MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT: 1XQ; “BRW” or the “Company”) is pleased to report the last results from the Mirage summer drilling campaign. The Mirage Project is located in the Eeyou Istchee-James Bay region of Quebec, approximately 40 kilometers south of the Trans-Taiga Road. This campaign focused on the Central Zone including the MR-6 and MR-3 dykes (see October 8, 2024 press release) and has continued to intersect wide and well-mineralized intervals on their extension and at depth. Highlights include:37 meters at 1.14% Li2O in hole MR-24-87 and 1.15% Li2O over 23 meters in hole MR-24-89 extending mineralization at MR-3 down dip where it remains open. New interval at the MR-6 Dyke with 1.74% Li2O over 19.7 meters in hole MR-24-84 and 0.93% Li2O over...

Oslo, 9 January 2025: Reference is made to the stock exchange notices published by Ultimovacs ASA (the “Company“) on (i) 17 December 2024 regarding the contemplated business combination between the Company and Zelluna Immunotherapy AS (the “Business Combination“) and the fully committed private placement with gross proceeds of approx. NOK 51.7 million (the “Private Placement“) and (ii) today on 9 January 2025 regarding the approval by an extraordinary general meeting of the Company (the “EGM“) of relevant resolutions related to the Business Combination and the Private Placement. The Business Combination and the Private Placement are hereinafter referred to as the “Transactions“. Following the EGM’s resolutions to approve the issuance of 167,864,598 shares in aggregate through...

Including market leading Arrow™ CVCs and Arterial Catheters WAYNE, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has been awarded a contract by Vizient, Inc., the largest provider-driven healthcare performance improvement company in the U.S. The agreement, effective January 1, 2025, covers the supply of Teleflex’s Central Venous Access Catheters and Arterial Catheters. Vizient provides solutions and services that improve the delivery of high-value care by aligning cost, quality, and market performance for more than 65% of the nation’s acute care providers. This includes 97% of the nation’s academic medical centers, and more than 35% of the acute care market. Vizient provides expertise, analytics, and advisory services, as well...